Financial Performance - Total revenues for 2024 increased by 21% to US$297.2 million, exceeding guidance of US$280-$295 million, driven by record RUCONEST® revenue and strong Joenja® growth [3][8][52] - RUCONEST® revenue for the full year 2024 was US$252.2 million, an 11% increase compared to 2023, while Joenja® revenue reached US$45.0 million, a 147% increase in its first full year of sales [8][52] - Fourth quarter 2024 total revenues increased by 14% to US$92.7 million compared to the same quarter in 2023, with RUCONEST® revenue at US$79.6 million (9% increase) and Joenja® revenue at US$13.1 million (66% increase) [8][44][49] Clinical Development and Pipeline - The company is advancing regulatory reviews for leniolisib in key markets and for pediatric use, with two ongoing Phase II trials for additional primary immunodeficiencies (PIDs) [4][27] - The acquisition of Abliva has been completed, adding KL1333 for mitochondrial diseases to the clinical pipeline, which has blockbuster potential [5][34] - Positive top-line results were announced for a Phase III trial of leniolisib in children aged 4 to 11, with global regulatory filings planned for the second half of 2025 [21][19] Market and Product Insights - The U.S. market contributed 98% of 2024 revenues, with the company focusing on expanding its portfolio in the U.S. and Joenja® in key countries [10][8] - The company identified over 880 diagnosed APDS patients globally, with ongoing initiatives to diagnose additional patients through genetic testing programs [14][15] - The strong growth in RUCONEST® revenue is attributed to new physician prescriptions and patient enrollments, with a 24% increase in total enrollments in 2024 [11][9] Financial Outlook - For 2025, the company anticipates total revenues between US$315 million and US$335 million, representing a growth of 6% to 13% [78] - The company plans to continue investing in its product portfolio and R&D pipeline, particularly for PIDs and primary mitochondrial diseases [7][78] - Operating expenses are expected to remain below the prior year's levels, with an estimated US$30 million in Abliva-related expenses [78]

Core Points - Pharming Group N.V. announced the adoption of all proposals at the Extraordinary General Meeting of Shareholders, including the appointment of Mr. Fabrice Chouraqui as Executive Director and CEO for a four-year term [1][2] - Mr. Chouraqui succeeds Mr. Sijmen de Vries, who will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition [2] - The remuneration package for Mr. Chouraqui was also approved by shareholders [2] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare and life-threatening diseases [5] - The company is engaged in the commercialization and development of protein replacement therapies and precision medicines, including small molecules and biologics [5] - Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [5] Leadership Commentary - Dr. Richard Peters, Chairman of the Board, expressed a warm welcome to Mr. Chouraqui and acknowledged the significant contributions of the outgoing CEO, Mr. de Vries, over the past 16 years [4]

Core Insights - Pharming Group N.V. will participate in the 37th Annual Roth Conference in Dana Point, California, from March 16-18, 2025, with a fireside chat scheduled for March 17 at 01:30 PM PT [1] - The company is focused on developing and commercializing innovative therapies for patients with rare and life-threatening diseases [3] Company Overview - Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands, with a presence in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [3] - The company specializes in protein replacement therapies and precision medicines, including small molecules and biologics [3]

Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases [5] - The company is engaged in the commercialization and development of an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics [5] - Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [5] Financial Reporting - Pharming will report its preliminary (unaudited) fourth quarter and full year 2024 financial results for the period ended December 31 on March 13, 2025 [1] - A presentation for analysts and investors will be hosted on the same day at 13:30 CET/08:30 am EDT [1] Conference Call Participation - Participants interested in the conference call must register in advance to receive dial-in information and a unique PIN [2] - The company will only take questions from dial-in attendees during the conference call [3]

Core Viewpoint - Pharming Group N.V. has nominated Fabrice Chouraqui as the new Executive Director and CEO, succeeding Sijmen de Vries, with the appointment to be confirmed at an upcoming Extraordinary General Meeting of Shareholders [1][2][3] Company Leadership Transition - Fabrice Chouraqui will be appointed for a term of four years, and Sijmen de Vries will resign from the Board but remain as a strategic advisor until December 31, 2025, to ensure a smooth transition [2][3] - Dr. Richard Peters, Chairman of the Board, expressed confidence in Chouraqui's ability to lead Pharming and implement its growth strategy in the rare disease sector [4] Fabrice Chouraqui's Background - Chouraqui is a seasoned global pharmaceutical executive with experience at Flagship Pioneering, Novartis, and Bristol-Myers Squibb, known for his leadership in launching treatments across various therapeutic areas [6][8][9] - He has a strong track record in developing commercial strategies and improving profitability, particularly during his tenure at Novartis [9][10] Strategic Vision - Chouraqui aims to build on Pharming's existing foundation and enhance its portfolio of products and commercial opportunities in the rare disease market [6][8] - His leadership is expected to drive Pharming's growth and position it as a leading company in the rare disease space [6][4]

Core Insights - Pharming Group N.V. announced topline results from a Phase 3 trial of leniolisib for children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS), a genetic disorder affecting the immune system [1][2] - Leniolisib, marketed as Joenja in the U.S., received FDA approval for APDS in patients aged 12 and older in March 2023, with plans to seek approval for younger patients starting in 2025 [2] Study Details - The Phase 3 study enrolled 21 children aged 4 to 11 years, focusing on primary efficacy endpoints such as reduction in lymph node size and increased proportion of naïve B cells after 12 weeks [3][5] - Secondary endpoints included evaluating the impact of leniolisib on health-related quality of life [4] Results - All 21 patients completed the 12-week treatment, showing improvement in lymphoproliferation and immunophenotype correction, consistent with previous results in older patients [5][6] - Treatment-emergent adverse events were mild to moderate, with no serious drug-related adverse events reported [6] Market Reaction - Following the announcement, PHAR stock increased by 11.6%, reaching $9.75 [7]

Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growth RUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023 Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023 On track for 2024 total revenue ...

Conference call registration: To watch the live webcast, please register in advance using the link below. About Pharming Group N.V. For further public information, contact: LifeSpring Life Sciences Communication, Amsterdam, The Netherlands Leon Melens T: +31 6 53 81 64 27 E: pharming@lifespring.nl To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. https://register.vevent. ...

Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conferences in the month of June: Jefferies Healthcare Conference, New York, USA, June 5-6, 2024 Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the "Upcoming Events" and "News" sections of Pharming's website. Oppenheimer Novel ...

A recording of the webcast, presentation slides from today's AGM, and more details regarding agenda items are available on the Company's website in the Investor Relations section. About Pharming Group N.V. Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr ...